Sildenafil citrate is under clinical development by XOMA Royalty and currently in Phase II for Female Hypoactive Sexual Desire Disorder. According to GlobalData, Phase II drugs for Female Hypoactive Sexual Desire Disorder have a 62% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Sildenafil citrate’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Sildenafil citrate overview
Sildenafil citrate (SST-6007) is under development for the treatment of female hypoactive sexual desire disorder. The drug candidate is a small molecule applied vaginally and topically to the female genitalia. It acts by targeting phosphodiesterase 5 (PDE-5). It is developed based on KNOSIS delivery technology.
XOMA Royalty overview
XOMA Corp (XOMA), formerly XOMA Ltd, is a biopharmaceutical company. It develops antibody-based therapeutics. The company leverages its proprietary products and platforms through strategic out-licensing agreements, while also targeting early to mid-stage clinical assets in Phase I and II, which have significant commercial potential and are now licensed to larger pharmaceutical partners. The company also secures lucrative revenue streams through the acquisition of milestone and royalty payments from late-stage clinical assets and commercial products that fill unmet medical needs. It operates through its subsidiaries in Bermuda, the UK, and the US. XOMA is headquartered in Berkeley, California, the US.
For a complete picture of Sildenafil citrate’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
